How kidney disease causes gynaecomastia is an important clinical question for the many men living with chronic kidney disease (CKD) or end-stage renal disease (ESRD). Gynaecomastia — the benign enlargement of glandular breast tissue in males — is a recognised complication of declining renal function, driven primarily by hormonal dysregulation. When the kidneys fail to metabolise and excrete hormones effectively, the balance between oestrogen and testosterone shifts, promoting breast tissue growth. Medications commonly used in CKD management can compound this risk. Understanding the underlying mechanisms helps guide appropriate investigation, treatment, and patient reassurance.

The Link Between Kidney Disease and Gynaecomastia

Kidney disease causes gynaecomastia through hormonal dysregulation, particularly an altered oestrogen-to-testosterone ratio resulting from impaired renal hormone metabolism. Successful renal transplantation may partially or fully resolve the condition in some patients.

Gynaecomastia — the benign enlargement of glandular breast tissue in males — is a recognised complication of chronic kidney disease (CKD) and end-stage renal disease (ESRD). Reported prevalence rates in men receiving dialysis vary considerably across studies, and figures should be interpreted with caution given differences in diagnostic criteria and study populations. Despite being a well-documented association, it may not always be addressed proactively in routine clinical practice.

The relationship between kidney disease and gynaecomastia is primarily driven by hormonal dysregulation. The kidneys play a central role in metabolising and excreting hormones, and when renal function declines, this process is disrupted. The resulting hormonal imbalance — particularly an altered ratio of oestrogen to testosterone — creates the physiological conditions that promote breast tissue proliferation.

It is important to note that gynaecomastia in the context of kidney disease is almost always benign. However, it can cause significant physical discomfort and psychological distress, including anxiety and reduced self-esteem. Recognising the link between renal disease and breast tissue changes is therefore important not only for clinical management but also for patient reassurance and quality of life.

It is also worth noting that successful renal transplantation can improve the endocrine abnormalities associated with CKD and may lead to partial or complete resolution of gynaecomastia in some patients.

How Kidney Disease Disrupts Hormone Balance

CKD disrupts the HPG axis via uraemic toxins, reducing testosterone synthesis, impairing oestrogen clearance, and elevating prolactin — collectively shifting the hormonal balance in favour of oestrogen-driven breast tissue proliferation.

The kidneys are integral to the regulation of the hypothalamic-pituitary-gonadal (HPG) axis, which governs the production and clearance of sex hormones. In CKD, the accumulation of uraemic toxins interferes with this axis at multiple levels, leading to a state of hypogonadism — reduced testosterone production — alongside relative hyperoestrogenaemia (elevated oestrogen activity).

Several mechanisms contribute to this hormonal disruption:

• Reduced testosterone synthesis: Uraemic toxins directly impair Leydig cell function in the testes, reducing testosterone production. CKD most commonly produces a pattern of hypogonadotropic hypogonadism, in which luteinising hormone (LH) and follicle-stimulating hormone (FSH) levels are low or inappropriately normal despite low testosterone; however, patterns vary between individuals and some patients may show elevated gonadotrophins.

• Increased oestrogen activity: The peripheral conversion of androgens to oestrogens (aromatisation) continues, and may be increased in the context of higher adiposity or other factors, whilst renal clearance of oestrogens is impaired. This leads to a relative excess of circulating oestrogens.

• Elevated prolactin: The kidneys normally contribute to prolactin clearance from the bloodstream. In renal failure, prolactin levels rise — a condition known as hyperprolactinaemia — which further suppresses testosterone and may independently stimulate breast tissue.

• Sex hormone-binding globulin (SHBG) changes: Alterations in SHBG levels in CKD are variable but can reduce the amount of free, biologically active testosterone available to tissues.

Together, these changes shift the oestrogen-to-testosterone ratio in favour of oestrogen, which binds to oestrogen receptors in breast tissue and stimulates ductal and stromal proliferation — the hallmark of gynaecomastia.

Other Factors That Contribute to Breast Tissue Changes

Medications such as spironolactone, digoxin, and antipsychotics are among the most significant additional contributors to gynaecomastia in CKD patients. Comorbidities including liver disease, thyroid dysfunction, and diabetes can further compound hormonal imbalance.

Whilst hormonal dysregulation from kidney disease itself is a primary driver, several additional factors commonly encountered in this patient population can independently or synergistically contribute to gynaecomastia.

Medications are among the most significant contributors. Many drugs used in the management of CKD and its complications are associated with gynaecomastia, including:

• Spironolactone — used for fluid overload, resistant hypertension, and heart failure in some CKD patients; it acts as an anti-androgen and is one of the most commonly implicated drug-related causes of gynaecomastia. Importantly, spironolactone can itself cause hyperkalaemia and must be used with caution and appropriate monitoring in CKD under specialist supervision.

• Digoxin — occasionally used in patients with concurrent cardiac disease; listed as a recognised cause of gynaecomastia in the BNF.

• Calcium channel blockers (e.g., amlodipine) — used for hypertension in CKD; an association with gynaecomastia has been reported in rare cases, though the evidence is largely based on case reports and the association should not be overstated.

• Proton pump inhibitors (e.g., omeprazole) — frequently prescribed in this population; similarly, any association with gynaecomastia is rare and based on limited case-report data.

• Anti-androgens and 5-alpha-reductase inhibitors (e.g., finasteride, dutasteride, bicalutamide) — if prescribed for concurrent conditions, these carry a well-established risk of gynaecomastia.

• Antipsychotics (e.g., risperidone) — can cause hyperprolactinaemia and thereby contribute to gynaecomastia.

If you think a medicine may be causing or worsening your symptoms, do not stop taking it without first speaking to your doctor. Suspected side effects from any medicine can be reported to the MHRA via the Yellow Card Scheme (yellowcard.mhra.gov.uk).

Malnutrition and weight loss, which are common in advanced CKD, can occasionally precipitate gynaecomastia through a transient hormonal shift favouring oestrogen activity during nutritional recovery, though this is uncommon and not well characterised in the CKD population specifically.

Comorbid conditions such as liver disease, thyroid dysfunction, and type 2 diabetes — all of which are more prevalent in CKD patients — can independently alter sex hormone metabolism and compound the risk. Alcohol use, which affects hepatic oestrogen metabolism, may also be a contributing factor in some individuals.

A thorough medication review and assessment of comorbidities is therefore essential when evaluating gynaecomastia in any patient with kidney disease, as addressing modifiable contributing factors may lead to partial or complete resolution.

Diagnosing Gynaecomastia in Patients With Kidney Disease

Diagnosis is primarily clinical, confirmed by palpating a firm glandular disc beneath the nipple; investigations include serum testosterone, LH, FSH, prolactin, and oestradiol. Unilateral, hard, or rapidly growing tissue warrants urgent suspected cancer referral per NICE NG12.

Diagnosis of gynaecomastia is primarily clinical, based on history and physical examination. The clinician will typically palpate a firm, rubbery disc of glandular tissue beneath the nipple-areolar complex, which distinguishes true gynaecomastia from pseudogynecomastia (fatty tissue deposition without glandular proliferation, more common in obesity).

In patients with known kidney disease, the clinical history should explore:

• Duration and progression of breast changes

• Current medications, including over-the-counter drugs and supplements

• Symptoms of hypogonadism such as reduced libido, fatigue, or erectile dysfunction

• Nipple discharge, skin changes, or unilateral hard masses — features that would raise concern for malignancy

Although male breast cancer is rare, it must be excluded, particularly in cases of unilateral, hard, or rapidly growing breast tissue. In line with NICE guidance (NG12: Suspected cancer — recognition and referral), an urgent suspected cancer (two-week-wait) referral should be made if malignancy is suspected.

Investigations typically include:

• Serum testosterone, LH, FSH, prolactin, and oestradiol — to characterise the hormonal profile

• Thyroid function tests and liver function tests — to exclude other systemic causes

• Renal function and eGFR — already monitored in CKD patients

• Testicular examination — to assess for testicular pathology; if a testicular tumour is suspected, serum human chorionic gonadotrophin (hCG) and alpha-fetoprotein (AFP) should be measured, and testicular ultrasound arranged

• Breast imaging — where the clinical picture is uncertain or malignancy cannot be excluded on examination alone, this is arranged via the symptomatic breast clinic as part of triple assessment (clinical examination, imaging — typically ultrasound ± mammography — and biopsy where indicated)

In dialysis patients, hormonal results must be interpreted cautiously, as reference ranges may not apply directly to this population due to altered hormone kinetics.

Treatment and Management Options

Management follows a stepwise approach: review causative medications, optimise renal replacement therapy, then consider off-label SERMs such as tamoxifen under specialist supervision. Surgical reduction mammoplasty is available for fibrotic, treatment-resistant cases subject to local ICB criteria.

Management of gynaecomastia in patients with kidney disease is guided by the underlying cause, severity of symptoms, and the patient's overall clinical status. The approach is broadly stepwise, beginning with addressing reversible causes before considering pharmacological or surgical intervention.

Step 1 — Review and modify contributing medications. Where clinically safe, switching or reducing the dose of causative drugs may lead to regression of breast tissue, particularly if gynaecomastia is in its early, active phase. For example, eplerenone has less anti-androgenic activity than spironolactone; however, both carry a risk of hyperkalaemia and eplerenone is contraindicated in severe CKD. Any change to mineralocorticoid receptor antagonist therapy must be clinician-led, with close monitoring of potassium and renal function. Medication changes should never be made without medical advice.

Step 2 — Optimise renal replacement therapy. In dialysis patients, improving the adequacy of dialysis may partially correct uraemia-related hormonal disturbances, though complete normalisation of the hormonal profile is rarely achieved through dialysis alone. Successful renal transplantation can have a more substantial effect on restoring hormonal balance and may reduce or resolve gynaecomastia in some patients.

Step 3 — Pharmacological treatment. For persistent or symptomatic gynaecomastia, the following agents may be considered under specialist supervision:

• Tamoxifen — a selective oestrogen receptor modulator (SERM); evidence supports its use in reducing breast pain and tissue volume, particularly in the active proliferative phase. It is important to note that tamoxifen is used off-label for this indication in men in the UK. It carries a risk of venous thromboembolism (VTE) and other side effects; use requires specialist initiation and monitoring.

• Raloxifene — an alternative SERM with a similar mechanism; also used off-label in men, with similar considerations regarding VTE risk and specialist oversight.

• Testosterone replacement — may be considered in confirmed hypogonadism, though its use in CKD requires careful specialist monitoring. Testosterone can initially worsen gynaecomastia through peripheral aromatisation to oestrogen, and monitoring of haematocrit and other parameters is required.

Step 4 — Surgical intervention. For longstanding, fibrotic gynaecomastia that has not responded to medical management, surgical reduction mammoplasty may be considered. NHS availability varies by region and is subject to local Integrated Care Board (ICB) criteria, often requiring an Individual Funding Request (IFR) and documented failure of conservative management.

Patient support, including psychological input where body image is significantly affected, should be offered alongside physical treatments.

When to Speak to Your GP or Specialist

Patients should seek prompt medical advice for any new breast swelling, tenderness, nipple discharge, or psychological distress related to body image changes. Hard, fixed, or unilateral lumps with skin changes require urgent assessment for possible male breast cancer under NICE NG12.

Patients with kidney disease who notice changes in their breast tissue should not feel alarmed, but they should seek medical advice promptly so that the cause can be properly assessed and managed. Early evaluation is important because gynaecomastia is most responsive to treatment during its active, proliferative phase — typically within the first 12 months of onset.

Contact your GP or renal team if you notice:

• Swelling, tenderness, or a lump beneath one or both nipples

• Nipple discharge of any kind

• Rapid growth or change in the appearance of breast tissue

• Psychological distress related to changes in your body image

• New symptoms of hypogonadism, such as significant fatigue, reduced libido, or mood changes

Seek prompt medical advice so that an urgent suspected cancer (two-week-wait) referral can be arranged if you experience:

• A hard, fixed, or painless lump — particularly if unilateral

• Skin dimpling, puckering, or ulceration over the breast

• Swollen lymph nodes in the armpit

These features may indicate male breast cancer and should be assessed urgently in line with NICE NG12 (Suspected cancer: recognition and referral) criteria.

For patients already under the care of a nephrologist or renal unit, raising concerns at your next scheduled appointment is appropriate for mild or slowly progressive changes. Your renal team can coordinate with endocrinology, urology, or breast surgery colleagues as needed. Open communication with your healthcare team ensures that both your kidney disease and any associated complications — including gynaecomastia — are managed holistically and in line with current NHS best practice.

If you believe a medicine is causing or worsening your symptoms, do not stop taking it without speaking to your doctor first. Suspected side effects from any medicine can be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

Frequently Asked Questions